000283017 001__ 283017
000283017 005__ 20251222092348.0
000283017 0247_ $$2doi$$a10.1016/j.fitote.2025.106968
000283017 0247_ $$2pmid$$apmid:41187864
000283017 0247_ $$2ISSN$$a0367-326X
000283017 0247_ $$2ISSN$$a1873-6971
000283017 037__ $$aDZNE-2025-01429
000283017 041__ $$aEnglish
000283017 082__ $$a570
000283017 1001_ $$ade Almeida Cruz, Tamires$$b0
000283017 245__ $$aCannabis sativa extracts reduce inclusion formation in a cell model of alpha-synuclein aggregation.
000283017 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2025
000283017 3367_ $$2DRIVER$$aarticle
000283017 3367_ $$2DataCite$$aOutput Types/Journal article
000283017 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1766391711_14398
000283017 3367_ $$2BibTeX$$aARTICLE
000283017 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000283017 3367_ $$00$$2EndNote$$aJournal Article
000283017 520__ $$aParkinson's disease (PD) is classified as a synucleinopathy due to the accumulation of protein inclusions rich in the alpha-synuclein (aSyn) protein. Identifying effective pharmacological therapies is important to slow the progression and minimize the symptoms of these diseases. Cannabis sativa has a diverse chemical profile depending on its genotype, including several classes of substances, such as cannabinoids, flavonoids, terpenes, and alkaloids. In this study, we evaluated the effects of four C. sativa extracts with different phytocannabinoid chemical profiles in two cellular models that reproduce alterations in cellular homeostasis common during the cellular phase of PD and other synucleinopathies. We used Saccharomyces cerevisiae strains transformed with plasmid DNA and genetically modified human cells (H4), both expressing aSyn. The results showed that all the extracts were antioxidants, decreasing intracellular oxidation levels and increasing the number of daughter cells in yeast cells, but did not prevent mitochondrial damage. Besides, the extracts reduced the number of intracellular inclusions in H4 cells and increased the number of cells without inclusions. Phytochemical characterization revealed extracts rich in Tetrahydrocannabinol - THC (69.88 %), Cannabidiol - CBD (52.64 %), and Cannabinol - CBN (47.38 % and 58.64 %), and we concluded that, regardless of these percentages, all C. sativa extracts showed protective biological activity against toxicity caused by alpha-synuclein production, both in yeast cells and H4 cells.
000283017 536__ $$0G:(DE-HGF)POF4-352$$a352 - Disease Mechanisms (POF4-352)$$cPOF4-352$$fPOF IV$$x0
000283017 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000283017 650_7 $$2Other$$aAlpha-synuclein
000283017 650_7 $$2Other$$aNeurodegeneration
000283017 650_7 $$2Other$$aParkinson's disease, cannabis sativa
000283017 650_7 $$2Other$$aProtein aggregation
000283017 7001_ $$ade Paulo Osorio, Rodrigo$$b1
000283017 7001_ $$ade Menezes Epifanio, Neide Mara$$b2
000283017 7001_ $$aMerghani, Madiha$$b3
000283017 7001_ $$aPereira, Marcos Dias$$b4
000283017 7001_ $$ade Almeida Chaves, Douglas Siqueira$$b5
000283017 7001_ $$0P:(DE-2719)2814138$$aOuteiro, Tiago Fleming$$b6$$udzne
000283017 7001_ $$aRiger, Cristiano Jorge$$b7
000283017 773__ $$0PERI:(DE-600)2027649-7$$a10.1016/j.fitote.2025.106968$$gVol. 188, p. 106968 -$$p106968$$tFitoterapia$$v188$$x0367-326X$$y2025
000283017 8564_ $$uhttps://pub.dzne.de/record/283017/files/DZNE-2025-1429_Restricted.pdf$$yRestricted
000283017 8564_ $$uhttps://pub.dzne.de/record/283017/files/DZNE-2025-1429_Restricted.pdf?subformat=pdfa$$xpdfa$$yRestricted
000283017 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814138$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000283017 9131_ $$0G:(DE-HGF)POF4-352$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vDisease Mechanisms$$x0
000283017 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFITOTERAPIA : 2022$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-07
000283017 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2025-01-07
000283017 9201_ $$0I:(DE-2719)1410002$$kAG Fischer$$lEpigenetics and Systems Medicine in Neurodegenerative Diseases$$x0
000283017 980__ $$ajournal
000283017 980__ $$aEDITORS
000283017 980__ $$aVDBINPRINT
000283017 980__ $$aI:(DE-2719)1410002
000283017 980__ $$aUNRESTRICTED